Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Rutkowski

Showing results (381-390 of 456) with videos related to

Pageof 46
Sort By:
The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
Cancer|August 16, 2020
Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWGWinan J van Houdt, Marco Fiore, Francesco Barretta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteriaAugustinus P T van der Ploeg, Alexander C J van Akkooi, Piotr Rutkowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2020
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced MelanomaCaroline Robert, Georgina V Long, Benjamin Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label StudyFilippo de Braud, Christophe Dooms, Rebecca S Heist, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
European Journal of Cancer (Oxford, England : 1990)|October 6, 2022
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 studyMuhammad A Khattak, Jason J Luke, Georgina V Long, et al.
Annals of Surgical Oncology|October 14, 2025
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III MelanomaElan Novis, Mervi Rautalin, Rodabe N Amaria, et al.
JAMA Oncology|November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 TrialPaolo A Ascierto, Georgina V Long, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label studyHans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.
Pageof 46

Showing results (381-390 of 456) with videos related to

Sort By:
Pageof 46
The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
Cancer|August 16, 2020
Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWGWinan J van Houdt, Marco Fiore, Francesco Barretta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteriaAugustinus P T van der Ploeg, Alexander C J van Akkooi, Piotr Rutkowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2020
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced MelanomaCaroline Robert, Georgina V Long, Benjamin Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label StudyFilippo de Braud, Christophe Dooms, Rebecca S Heist, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
European Journal of Cancer (Oxford, England : 1990)|October 6, 2022
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 studyMuhammad A Khattak, Jason J Luke, Georgina V Long, et al.
Annals of Surgical Oncology|October 14, 2025
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III MelanomaElan Novis, Mervi Rautalin, Rodabe N Amaria, et al.
JAMA Oncology|November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 TrialPaolo A Ascierto, Georgina V Long, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label studyHans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.
Pageof 46